Printer Friendly

Genentech Presents Pivotal Phase III CLL14 Results for Venclexta in Combination with Gazyva for Chronic Lymphocytic Leukemia.

M2 PHARMA-June 6, 2019-Genentech Presents Pivotal Phase III CLL14 Results for Venclexta in Combination with Gazyva for Chronic Lymphocytic Leukemia

(C)2019 M2 COMMUNICATIONS

- US-based Genentech, a member of Switzerland's Roche Group (SIX: RO) (OTCQX: RHHBY) has presented results from the pivotal Phase III CLL14 study in previously untreated chronic lymphocytic leukemia showing that Venclexta (venetoclax) plus Gazyva (obinutuzumab) met its primary endpoint of investigator-assessed progression-free survival, the company said.

The 12-month, fixed-duration, chemotherapy-free combination reduced the risk of disease worsening or death by 65% compared to Gazyva plus chlorambucil (PFS, as assessed by investigator; HR=0.35; 95 % CI 0.23-0.53; p

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 6, 2019
Words:115
Previous Article:EpimAb Biotherapeutics Raises USD 74m in Series B Financing.
Next Article:Celgene Shows Data from Ongoing Studies of Liso-Cel in Patients with Difficult-to-Treat Blood Cancers at ASCO 2019.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters